ロード中...
The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas
Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat(®), Temodal(®) or Temodar(®)) is a first-line treatment for malignant gliomas but the development of drug resistance remains a major concern. Activating transcription factor 4 (ATF4) is a c...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584239/ https://ncbi.nlm.nih.gov/pubmed/28881638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17737 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|